156 related articles for article (PubMed ID: 27814414)
1. A boxed warning for inadequate psoriasis treatment.
Kagha KC; Blauvelt A; Anderson KL; Leonardi CL; Feldman SR
Cutis; 2016 Sep; 98(3):206-207. PubMed ID: 27814414
[No Abstract] [Full Text] [Related]
2. The FDA guidelines for the treatment of psoriasis using cyclosporine A: are they adequate?
Zackheim HS
Cutis; 2002 Nov; 70(5):288-90. PubMed ID: 12469783
[TBL] [Abstract][Full Text] [Related]
3. Dermatologic agents during pregnancy and lactation: an update and clinical review.
Hale EK; Pomeranz MK
Int J Dermatol; 2002 Apr; 41(4):197-203. PubMed ID: 12031026
[No Abstract] [Full Text] [Related]
4. Retinoid therapy for psoriasis.
Yamauchi PS; Rizk D; Lowe NJ
Dermatol Clin; 2004 Oct; 22(4):467-76, x. PubMed ID: 15450342
[TBL] [Abstract][Full Text] [Related]
5. Long-term efficacy of biologics in the treatment of psoriasis: what do we really know?
Alwawi EA; Krulig E; Gordon KB
Dermatol Ther; 2009; 22(5):431-40. PubMed ID: 19845720
[TBL] [Abstract][Full Text] [Related]
6. The only topical retinoid without a generic alternative: tazarotene.
Kircik LH
J Drugs Dermatol; 2013 Mar; 12(3):s52. PubMed ID: 23545934
[No Abstract] [Full Text] [Related]
7. Pediatric psoriasis: updates in biologic therapies.
Sukhatme SV; Gottlieb AB
Dermatol Ther; 2009; 22(1):34-9. PubMed ID: 19222515
[TBL] [Abstract][Full Text] [Related]
8. The Value of the Black Box Warning in Dermatology.
Winterfield L; Vleugels RA; Park KK
J Drugs Dermatol; 2015 Jul; 14(7):660-6. PubMed ID: 26151780
[TBL] [Abstract][Full Text] [Related]
9. Drug Survival Studies in Dermatology:Principles, Purposes, and Pitfalls.
van den Reek JMPA; Kievit W; Gniadecki R; Goeman JJ; Zweegers J; van de Kerkhof PCM; Seyger MMB; de Jong EMGJ
J Invest Dermatol; 2015 Jul; 135(7):1-5. PubMed ID: 26066896
[No Abstract] [Full Text] [Related]
10. iCHANGE.
Weinberg JM
Cutis; 2008 Jan; 81(1):21. PubMed ID: 18306841
[No Abstract] [Full Text] [Related]
11. Ustekinumab (Stelara) for psoriasis.
Med Lett Drugs Ther; 2010 Jan; 52(1330):7-8. PubMed ID: 20208473
[No Abstract] [Full Text] [Related]
12. Folate with methotrexate: big benefit, questionable cost.
Brownell I; Strober BE
Br J Dermatol; 2007 Jul; 157(1):213. PubMed ID: 17578449
[No Abstract] [Full Text] [Related]
13. [Off-label use].
Fritz K; Augustin M; John SM
Hautarzt; 2013 Oct; 64(10):727. PubMed ID: 24150819
[No Abstract] [Full Text] [Related]
14. Safety of dermatologic medications in pregnancy and lactation: Part I. Pregnancy.
Murase JE; Heller MM; Butler DC
J Am Acad Dermatol; 2014 Mar; 70(3):401.e1-14; quiz 415. PubMed ID: 24528911
[TBL] [Abstract][Full Text] [Related]
15. Summaries of safety labeling changes approved by FDA-Boxed warnings highlights, October-December 2019.
Am J Health Syst Pharm; 2020 Apr; 77(8):e6-e8. PubMed ID: 32236460
[No Abstract] [Full Text] [Related]
16. FDA weighs communicating drug-related risk to patients.
Stephenson J
JAMA; 1999 Aug; 282(6):515. PubMed ID: 10450699
[No Abstract] [Full Text] [Related]
17. Emerging oral drugs for psoriasis.
Mahmood T; Zaghi D; Menter A
Expert Opin Emerg Drugs; 2015 Jun; 20(2):209-20. PubMed ID: 25643592
[TBL] [Abstract][Full Text] [Related]
18. Summaries of safety labeling changes approved by FDA-Boxed warnings highlights October-December 2015.
Office of Health & Constituent Affairs U.S. Food and Drug Administration
Am J Health Syst Pharm; 2016 Mar; 73(5):267. PubMed ID: 26896495
[No Abstract] [Full Text] [Related]
19. Summaries of safety labeling changes approved by FDA-Boxed warnings highlights, January-March 2019.
Am J Health Syst Pharm; 2019 Jun; 76(13):e8-e9. PubMed ID: 31361888
[No Abstract] [Full Text] [Related]
20. Safety of dermatologic medications in pregnancy and lactation: Part II. Lactation.
Butler DC; Heller MM; Murase JE
J Am Acad Dermatol; 2014 Mar; 70(3):417.e1-10; quiz 427. PubMed ID: 24528912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
